Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

September 1, 2017

Primary Completion Date

May 27, 2020

Study Completion Date

May 27, 2020

Conditions

Chronic Myelogenous Leukemia, Ph1-PositiveAcute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

BP1001 (varying dose)

DRUG

BP1001 (fixed dose)

DRUG

Dasatinib

Trial Locations (1)

The University of Texas M.D. Anderson Cancer Center, Houston